Highlights from IMS 2025: progress in the understanding and treatment of precursor conditions Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, shares his approach to considering frailty in At the 2025 International Myeloma Society (IMS) Annual Meeting, Anaïs Schavgoulidze, PharmD, presents new research
Using MRD Status to Guide Care after Quad Induction in Myeloma | Elizabeth O'Donnell, MD | #IMS25 Dr. Craig Cole shares insights from the IMS 2025 meeting on advancing equitable myeloma care in low- and middle-income
Endogenous immune profiles linked to PFS in patients with RRMM treated with CAR T-cells In multiple myeloma care, timing can play a big role in treatment decisions. At the 2025 International Myeloma Society (IMS)
Ashley Rosko, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, comments on the importance of Updates from IMS on CAR-T & Bispecifics in Myeloma | Rahul Banerjee, MD | #IMS2025
Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX, comments on the role of measurable residual disease IMS 2025: Top 6 Presentations With Dr Rahul Banerjee - Cancer
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare IMS Highlights: Frontline Wins, High-Risk Insights, and What's Next in Myeloma The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
Likely Change in IMWG Myeloma Response Criteria : 24-Hour Urine & More | Rahul Banerjee, MD | #IMS25 Global Myeloma Care: Addressing Gaps in Low- and Middle-Income Countries | Craig Cole, MD | #IMS2025 IMF Chief Medical Officer Dr. Joseph Mikhael shares the latest research from the 2025 International Myeloma Society meeting in
Lymphocyte Count Used to Predict Delayed Neurotoxicity in Myeloma CAR-T | Hitomi Hosoya MD #ims25 Kwee Yong, MD, PhD, FRCP, FRCPath, University College London, London, UK, discusses progress being made in the IMS 2025 Promo
IMS 2025 Highlight: Myeloma Treatment Is Changing Fast | Mohamad Mohty, MD, PhD | #IMS2025 Join Dr. Claudio Cerchione as he shares the latest breakthroughs and clinical insights from the 2025 International Myeloma
IMF Chief Medical Officer Dr. Joseph Mikhael discusses the latest updates from the 2025 International Myeloma Society (IMS) Time Constraints and Myeloma Treatment Decisions | Arturo Hurtado | #IMS2025
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, shares details of a consensus paper to guide How MRD Status Is Being Used to Guide Myeloma Treatment Decisions | Ben Derman MD #IMS25
Dr. Paul Richardson presents promising IMS 2025 data on mezigdomide, an oral agent showing high response rates in relapsed Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma IMS 2025 Updates with Dr. Alfred Garfall
The potential of circulating tumor cells to clinically assess multiple myeloma and its precursors The treatment landscape for patients with multiple myeloma at first relapse
Krina Patel, MD, MSc, co–editor-in-chief of Blood Cancers Today, is section chief and research lead for multiple myeloma (MM) at Frailty-adapted treatment in newly diagnosed multiple myeloma
Meet the Expert Session at IMS 2025: outpatient administration of immunotherapy for myeloma Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of a study on genomic drivers
Limitations of current risk stratification tools for multiple myeloma About the 22nd IMS Annual Meeting The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, The 22nd International Myeloma Society (IMS) Annual Meeting was held in Toronto, Canada, from September 17-20, 2025. This meeting brought together leading
Updates from the 2025 International Myeloma Society (IMS) meeting. This week, the International Myeloma Society (IMS) is hosting its 22nd Annual Meeting—the world's largest gathering of multiple myeloma researchers and Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
Diana Cirstea, MD, Massachusetts Cancer Center, Boston, MA, discusses the BOSS program experience in multiple myeloma, Quadruplet regimens in transplant-ineligible NDMM: the new standard of care Lymphocyte counts may help predict delayed neurotoxicity in patients receiving CAR-T cell therapy for multiple myeloma. In this
Published in the Journal of Clinical Oncology, the peer-reviewed article, "International Myeloma Society/International Myeloma Working Group Genomic drivers of resistance to anti-BCMA immunotherapies in multiple myeloma In this JCO Article Insights episode, Michael Hughes summarizes "International Myeloma Society and International Myeloma
Risk stratification in smoldering myeloma: current standards and emerging advances IMS 2025 | Relapsed/refractory multiple myeloma
IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023 At IMS 2025, Dr. Rahul Banerjee (Fred Hutch) shares key updates from other investigators, including long-term cilta-cel outcomes, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses mechanisms of resistance and predictors of response to
Improving CAR T-cell responsiveness and overcoming resistance in multiple myeloma IMS Highlights: Frontline Wins, High-Risk Insights, and What's Next in Myeloma | Part 1 of 2 Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current treatment landscape for patients with
Dr. Joseph Mikhael (IMF Chief Medical Officer) breaks down the biggest takeaways from the International Myeloma Society Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, comments on the importance of bridging therapy prior to CAR T-cell therapy
Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, comments on the evolving use of measurable residual Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy,
In this video, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the most important research updates from the Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma
IMS 2025: Day 1 Features Encouraging Results for Patients with The International Myeloma Society Annual meeting.
In our upcoming Livestream session, Dr. Jesus Berdeja and Dr. Keith Steweart will provide updates on the latest myeloma Interview with Irene Ghobrial, MD from the Dana Farber Cancer institute. Filmed at IMS September 28th, 2023. The HealthTree How is minimal residual disease (MRD) being used in real-world myeloma care? In this presentation from the International
The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives Congress Materials – International Myeloma Society (IMS 2025)
5 Multiple Myeloma Research Highlights: 2024 International Myeloma Society Meeting | For Patients International Myeloma Society: Home
Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, comments on the potential of combining CELMoDs with T-cell The BOSS program: improving the safety of bispecific outpatient step-up dosing for multiple myeloma Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of circulating tumor cells (CTCs) to
At IMS 2025, Mohamad Mohty, MD, PhD, shares the latest updates on quadruplets, transplant debates, MRD-guided maintenance 2025 International Myeloma Society Annual Meeting
The IRAKLIA trial: isatuximab subcutaneous via OBI versus IV in RRMM IMS 2025 | VJHemOnc
Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved
Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, comments on the management of toxicities The role of MRD in guiding maintenance treatment decisions in multiple myeloma
This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) At IMS 2025, Dr. O'Donnell highlights new insights on quadruplets, maintenance, and the role of MRD in risk-adapted care. 5 Multiple Myeloma Research Highlights: 2024 International Myeloma Society Meeting | For Patients The International Myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares updates The CELMoD, Mezigdomide, Shows Dramatic Results in Relapsed Myeloma | Paul Richardson, MD | #IMS25 Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS
Interview with Sagar Lonial, MD, FACP from Winship Cancer Institute Of Emory University. Filmed at IMS September 29th, 2023. Myeloma Society's 22nd Annual Meeting (IMS 2025). What I found to be unique about this year's meeting was that some of the most intriguing Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, comments on the value of the quadruplet-based regimens
IMF Chief Medical Officer Dr. Joseph Mikhael shares the latest lessons on myeloma treatment shared at the 2025 International 22nd IMS Annual Meeting - International Myeloma Society
Using a Single Cell Approach to Define Mechanisms of Progression | Irene Ghobrial, MD | IMS 2023 A genomic consensus model for high-risk myeloma using NGS | Anais Schavgoulidze, PharmD #ims2025
Saurabh Zanwar, MBBS, Mayo Clinic, Rochester, MN, addresses the limitations of current risk stratification tools for multiple Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at Considering frailty in myeloma treatment decisions: advice for clinicians
Dr. Rahul Banerjee discusses upcoming revisions to the IMWG response criteria — including less reliance on 24-hour urine tests Ongoing trials for newly diagnosed myeloma in the UK: FiTNESS and iFit Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment
Longer Survival With Better Quality of Life: CAR-T for Multiple Myeloma Updates on current research exploring treatment strategies for high-risk smoldering myeloma Two types of resistance to BCMA-directed treatments in multiple myeloma: how do they differ?
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the Phase III IRAKLIA trial (NCT05405166), Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on the growing recognition of outpatient administration of IMS-IMWG Consensus Definition of HRMM | Int'l Myeloma Foundation
High-Risk Smoldering Myeloma & New Frontline Treatment: What Patients Need to Know | IMS Part 2 of 2 Key Updates from IMS 2025 | Claudio Cerchione, MD | #IMS2025
Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses two different types of resistance to IMS 2025 | Newly diagnosed multiple myeloma FAQs on Multiple Myeloma Highlights From the International Myeloma Society Annual Meeting
Stay up to date with the latest developments in newly diagnosed multiple myeloma from the 22nd IMS Annual Meeting with our live social media Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current standard and future of risk stratification in The evolving definition of high-risk multiple myeloma: new criteria
Anti-CD38–based quadruplet regimens for patients with transplant-ineligible multiple myeloma Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses strategies to improve CAR T-cell JCO Article Insights: IMS-IMWG Consensus on High-Risk Multiple Myeloma
Stay up to date with the latest developments in relapsed/refractory multiple myeloma from the 22nd IMS Annual Meeting with our live social